Clinical Trial Update: CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the CD-RCHOP regimen in newly diagnosed diffuse large B-cell lymphoma with TP53 mutation and 17p deletion; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Ruijin Hospital | Conditions: DLBCL | Phase 2 | Status: NOT_YET_RECRUITING